Top Industry Leaders in the Chronic Granulomatous Disease Market
Merck & Co. Received US FDA priority review for sotatercept, an experimental therapy for CGD and other progressive blood vessel disorders. Target action date for the review is March 26, 2024. Approval would solidify Merck's position in the CGD market.
Valenta Pharmaceuticals Launched Ethoxidol, a new generation antioxidant for treating chronic brain ischemia (cerebrovascular insufficiency) associated with CGD.Ethoxidol's unique mechanism of action has the potential to improve outcomes for patients with CGD
CGD Society Advocating for increased research funding and development of new therapies for CGD, including gene therapy and stem cell therapy.Hosting educational events and awareness campaigns to improve diagnosis and patient support.
List of Chronic Granulomatous Disease Key Companies in the Market
- Pfizer Inc.
- InterMune Inc.
- Novartis AG
- Lonza Group
- GlaxoSmithKline Plc
- Eli Lilly and Company
- Janssen Pharmaceuticals
- Merck KGaA
- Osiris Therapeutics Inc
- JCR Pharmaceuticals Co.Ltd.
- Maxcyte Inc.
- and Horizon Pharma Plc